2025-06-11 バッファロー大学
<関連情報>
- https://www.buffalo.edu/news/releases/2025/06/Non-opioid-relieves-chronic-pain.html
- https://journals.lww.com/pain/fulltext/2025/05000/pharmacologically_enabling_the_degradation_of.24.aspx
薬理学的にNaV1.8チャネルの分解を可能にし、神経障害性疼痛を軽減する Pharmacologically enabling the degradation of NaV1.8 channels to reduce neuropathic pain
Martin, Molly K; Rodriguez, Raider; Guerrero, Giselle; Sheehan, Garrett D.; Powell, Rasheen; Klein, Amanda H.; Bhattacharjee, Arin
Pain Published:May 2025
DOI:10.1097/j.pain.0000000000003470
Abstract
In phase II clinical trials, NaV1.8 channels were identified as viable targets to treat acute pain. Results were modest, however, and NaV1.8 pore blockers must be given systemically, potentially leading to adverse effects, especially during prolonged use. A local, long-lasting approach is desirable, yet local anesthetics are neither specific nor long-lasting. In lieu of a pore blocker approach, we show a pharmacological method targeting the scaffolding and degradation of NaV1.8 channels, which attenuated neuropathic pain behavior in mice. NaV1.8 channels interact with the WW domain–containing scaffold protein called Magi-1. WW domains are typically found in ubiquitin ligases, and NaV1.8 channels are susceptible to degradation by ubiquitin ligases. Here, we show NaV1.8 and MAGI-1 colocalized in human tissues. We demonstrate that a lipidated peptide derived from the NaV1.8 WW binding domain, at sub-micromolar concentrations, inhibited rodent dorsal root ganglion neuronal firing. The peptide reduced NaV1.8 channel immunoreactivity and tetrodotoxin-resistant currents in human dorsal root ganglion neurons. We found that the lipidated peptide attenuated neuropathic pain behaviors in mice for multiple weeks after a single injection. Our results reveal that the NaV1.8-targeted lipidated peptide provides local and sustained analgesia, serving as a viable alternative to NaV1.8 pore blockers.
